For children with sickle cell anemia in sub-Saharan Africa, infections are not a complication — they are a leading killer, and existing prophylactic strategies have not eliminated this burden. A rigorous Phase II randomized controlled trial now offers a low-cost, accessible adjunct that meaningfully reduces infection frequency in this high-risk pediatric population, potentially reshaping adjunct care protocols in resource-limited settings.
The ZIPS-2 trial enrolled 100 Ugandan children aged one to five years with confirmed sickle cell anemia at Jinja Regional Referral Hospital, randomly assigning them to either 20 mg of zinc sulfate daily or placebo for six months. Nearly half of participants were concurrently receiving hydroxyurea, and all were transitioned onto hydroxyurea during the trial — an important design feature that tests zinc's additive benefit atop standard therapy rather than in isolation. The zinc group recorded 80 all-cause infections versus 124 in the placebo group, a statistically significant reduction that translates to roughly a one-third lower infection rate per 100 person-years. Notably, there was zero loss to follow-up, lending confidence to the completeness of the outcome data.
Zinc's immunomodulatory role is well established: it supports neutrophil function, natural killer cell activity, and epithelial barrier integrity — all compromised in sickle cell disease. Prior zinc supplementation trials in general pediatric populations in low-income countries have shown modest infection-reduction benefits, but this is among the first powered, double-blind trials targeting sickle cell anemia specifically. Key limitations include the relatively small cohort size of 100 children, single-site design, and a six-month observation window that cannot assess long-term safety or sustained efficacy. Whether benefits extend to older children or to those not receiving hydroxyurea remains unknown. Nonetheless, given zinc's safety profile, low cost, and now demonstrated efficacy in this population, this trial carries real translational weight — incremental in mechanism but potentially paradigm-shifting in practice for under-resourced sickle cell programs across Africa.